6621 Effect of macroscopic vascular invasion (MVI), extrahepatic spread (EHS), and ECOG performance status (ECOG PS) on outcome in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib: analysis of two phase III, randomized, double-blind trials

J.Raoul; A.L.Cheng; Y.K.Kang; C.J.Tsao; J.Zou; A.Nadel; K.Burock; D.Voliotis; J.M.Llovet; J.Bruix

首页> 外文期刊>European Journal of Cancer Supplements >6621 Effect of macroscopic vascular invasion (MVI), extrahepatic spread (EHS), and ECOG performance status (ECOG PS) on outcome in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib: analysis of two phase III, randomized, double-blind trials

【24h】

6621 Effect of macroscopic vascular invasion (MVI), extrahepatic spread (EHS), and ECOG performance status (ECOG PS) on outcome in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib: analysis of two phase III, randomized, double-blind trials

机译：6621索拉非尼治疗的晚期肝细胞癌（HCC）患者的宏观血管侵犯（MVI），肝外扩散（EHS）和ECOG表现状态（ECOG PS）的效果：两个III期，随机，双盲分析试验

获取原文

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European Journal of Cancer Supplements》 |2009年第2期|共1页
作者
J.Raoul; A.L.Cheng; Y.K.Kang; C.J.Tsao; J.Zou; A.Nadel; K.Burock; D.Voliotis; J.M.Llovet; J.Bruix;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献

1. 6519 Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma (HCC): collective results from the phase III sorafenib HCC assessment randomized protocol (SHARP) and Asia-Pacific (AP) trials [J] . J.Llovet, A.Cheng, S.Qin, European Journal of Cancer Supplements . 2009,第2期

机译：6519索拉非尼在晚期肝细胞癌（HCC）患者中的疗效和安全性：索拉非尼三期HCC评估随机方案（SHARP）和亚太地区（AP）试验的综合结果
2. SEARCH: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Sorafenib Plus Erlotinib in Patients With Advanced Hepatocellular Carcinoma [J] . Zhu Andrew X., Rosmorduc Olivier, Evans T. R. Jeffry, Journal of Clinical Oncology . 2015,第6期

机译：搜索：晚期肝细胞癌患者中索拉非尼加厄洛替尼的III期，随机，双盲，安慰剂对照试验
3. BEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor, RAF Kinase, and Mammalian Target of Rapamycin Combination Targeted Therapy With Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell CarcinomaA Trial of the ECOG-ACRIN Cancer Research Group (E2804) [J] . Flaherty Keith T., Manola Judith B., Pins Michael, Journal of Clinical Oncology . 2015,第21期

机译：最佳：一项针对晚期肾细胞癌的血管内皮生长因子，RAF激酶和雷帕霉素联合靶向治疗与贝伐单抗，索拉非尼和替莫罗莫司联合靶向治疗的随机II期临床研究ECOG-ACRIN癌症研究组（E2804）的试验
4. BEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor RAF Kinase and Mammalian Target of Rapamycin Combination Targeted Therapy With Bevacizumab Sorafenib and Temsirolimus in Advanced Renal Cell Carcinoma—A Trial of the ECOG–ACRIN Cancer Research Group (E2804) [O] . Keith T. Flaherty, Judith B. Manola, Michael Pins, -1

机译：最佳：一项针对晚期肾细胞癌的血管内皮生长因子RAF激酶和雷帕霉素联合靶向治疗与贝伐单抗索拉非尼和替米罗莫司联合靶向治疗的随机II期临床研究-ECOG-ACRIN癌症研究小组的一项试验（E2804）
5. Search: A phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma [O] . Zhu Andrew X., Rosmorduc Olivier, Evans T.R. Jeffry, 2017

机译：搜索：索拉非尼联合厄洛替尼治疗晚期肝细胞癌的一项随机，双盲，安慰剂对照III期临床试验

6621 Effect of macroscopic vascular invasion (MVI), extrahepatic spread (EHS), and ECOG performance status (ECOG PS) on outcome in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib: analysis of two phase III, randomized, double-blind trials

著录项

相似文献

相关主题

期刊订阅